8-KLeadership Changes

DEXCOM INC 8-K Report, Executive Changes (Nov 7, 2007)

Filed November 7, 2007For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K report on November 7, 2007, announcing a significant change in its Board of Directors. Effective November 6, 2007, Kevin R. Sayer was appointed as a Class I director and also joined the Audit Committee. Mr. Sayer brings extensive financial and leadership experience from previous roles at medical technology companies, including Biosensors International Group, Ltd., Specialty Laboratories, Inc., and notably, as Chief Financial Officer of MiniMed, Inc., prior to its acquisition by Medtronic. This appointment is important for investors as it signals a strengthening of the Board's financial oversight and governance. Mr. Sayer's compensation package, which includes a cash retainer (partially paid in stock), and substantial stock options vesting over time, reflects the company's strategy to align executive and director incentives with shareholder value. His background, particularly his experience with diabetes-focused medical device companies like MiniMed, could be highly relevant to DexCom's strategic direction.

Key Highlights

  • 1Appointment of Kevin R. Sayer as a Class I director, with his term expiring in 2009.
  • 2Mr. Sayer has been appointed to the Audit Committee of the Board of Directors.
  • 3Mr. Sayer's compensation includes an annual retainer of $30,000, with at least 50% payable in DexCom common stock.
  • 4Upon appointment, Mr. Sayer received a stock option grant with a Black-Scholes value of $300,000, vesting monthly over 36 months.
  • 5Annual stock option grants of $125,000 (Black-Scholes value) are to be awarded for each subsequent year of service, vesting monthly over 12 months.
  • 6Mr. Sayer has a strong background in the medical technology and healthcare sectors, including significant experience with diabetes-related companies like MiniMed, Inc.

Frequently Asked Questions

Kevin R. Sayer is a seasoned executive with extensive experience in the medical technology and healthcare industries. He was appointed as a Class I director and to the Audit Committee to strengthen the Board's financial oversight and leverage his industry expertise, particularly his past roles with diabetes-focused companies.

Mr. Sayer will receive an annual retainer of $30,000, with the option to receive 50-100% in DexCom common stock. He also received an initial stock option grant valued at $300,000, which vests over three years. Additionally, he will receive annual stock option grants valued at $125,000 that vest over one year.

Mr. Sayer's career includes serving as CFO of MiniMed, Inc., a company focused on insulin pumps for diabetes management, before its acquisition by Medtronic. This direct experience with diabetes technology and its commercialization is highly relevant to DexCom's business as a leader in continuous glucose monitoring.

The stock options are designed to align Mr. Sayer's interests with those of DexCom shareholders. The vesting schedules over 12 to 36 months incentivize long-term commitment and performance, as the value of his compensation is directly tied to the company's stock performance over time.